“Global Migraine Drugs market is anticipated to surpass USD 7 Bn by 2030”

16 October 2019

Visiongain has launched a new pharma report ‘Migraine Drugs Market Report 2020-2030’’ by Product Type (Acute Migraine Treatment, Preventive Migraine Treatment), Route of Administration (Oral, Injection, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online), and Geography.

Global Migraine Drugs market is anticipated to grow on account of the growing prevalence of migraine. The global Migraine Drugs market is anticipated to grow at a lucrative CAGR of 12.4% and anticipated to surpass USD 7 Billion by 2030.

Migraine is highly common and ranked as the world's third most common disease. Nearly 1 in 4 U.S. families are suffering from migraine, although the effect on females is overwhelmingly weighted: 85% of chronic migraine sufferers are females. Most individuals are affected by migraine once or twice a month, however, chronic migraine has more than 4 million individuals. Migraine not only leads to substantial costs on people and society but is also associated with a reduced quality of life, often leading to lost job and family life being interrupted. Migraine also increases the danger of asthma, stroke, anxiety, and depression, as well as other pain disorders.

In the United States, the medical cost of chronic migraine treatment was over USD 5.4 billion in the year 2015. Overall, it is anticipated that combined annual health care and lost migraine-related productivity expenses are as large as USD 36 billion.

The growing prevalence of migraine is boosting the growth of migraine drug markets across the globe. Also, the growing female population and increasing awareness among patients associated with migraine prevention and treatment are important factors owing to market growth. Nevertheless, migraine-related side effects are a factor that hinders the market growth. On the contrary, it is anticipated that the existence of growth prospects in emerging nations will provide important players with fresh opportunities.

The U.S. dominated the market with more than 45% share in 2018 and is anticipated to maintain its position until the first half of the forecast period. Launch of calcitonin gene-related peptide (CGRP) based therapies, increasing adoption of novel therapeutics, high prevalence, and a large patient pool in the U.S. are some of the major factors contributing to the growth of migraine drugs market in the region. Emerging economies in the Asia Pacific are being driven by low-cost production of drugs, increasing healthcare expenditure, a large underserved patient pool, and growing disease awareness among other prominent factors.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the global migraine drugs market. Companies are also increasing their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the market.

The comprehensive market report features companies such as Abbott Laboratories, Aegis Therapeutics, LLC., Allergan, Amgen, Astrazeneca PLC, Eli Lilly & Company, Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Johnson & Johnson, Merck & Co., Novartis International AG, Pfizer, Sanofi SA, and Teva Pharmaceutical Industries Limited among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020–2030 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021


Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021


Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021


Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021